Nantahala Capital Management LLC Buys 7,571,636 Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Nantahala Capital Management LLC boosted its stake in Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 268.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,391,994 shares of the company's stock after purchasing an additional 7,571,636 shares during the quarter. Nantahala Capital Management LLC owned about 10.01% of Unicycive Therapeutics worth $8,253,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Virtu Financial LLC lifted its holdings in shares of Unicycive Therapeutics by 566.8% during the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock worth $30,000 after acquiring an additional 62,881 shares during the last quarter. Northern Trust Corp lifted its stake in Unicycive Therapeutics by 142.4% during the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock worth $46,000 after purchasing an additional 34,183 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Unicycive Therapeutics by 142.2% in the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock worth $136,000 after purchasing an additional 100,679 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after purchasing an additional 122,089 shares during the last quarter. Finally, Vivo Capital LLC raised its holdings in shares of Unicycive Therapeutics by 123.0% during the 4th quarter. Vivo Capital LLC now owns 9,970,152 shares of the company's stock valued at $7,918,000 after buying an additional 5,500,000 shares in the last quarter. 40.42% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

UNCY has been the topic of a number of recent research reports. Guggenheim initiated coverage on shares of Unicycive Therapeutics in a research report on Monday, April 21st. They set a "buy" rating and a $6.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $7.50 target price on shares of Unicycive Therapeutics in a research report on Friday, April 11th.

Unicycive Therapeutics Trading Up 0.3 %

UNCY stock traded up $0.00 during midday trading on Friday, hitting $0.65. The company had a trading volume of 485,088 shares, compared to its average volume of 1,451,074. The stock has a market cap of $78.06 million, a price-to-earnings ratio of -0.67 and a beta of 2.15. Unicycive Therapeutics, Inc. has a 52 week low of $0.20 and a 52 week high of $1.21. The stock's 50 day moving average price is $0.59 and its 200 day moving average price is $0.60.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Analysts predict that Unicycive Therapeutics, Inc. will post -0.23 earnings per share for the current year.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.